Status:
COMPLETED
A Continuation Trial for Subjects With Lupus That Completed Protocol HGS1006-C1056 or HGS1006-C1057
Lead Sponsor:
Human Genome Sciences Inc., a GSK Company
Collaborating Sponsors:
GlaxoSmithKline
Conditions:
Systemic Lupus Erythematosus
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This is a long-term continuation study to provide continuing treatment to subjects with SLE.
Detailed Description
This trial is a long-term continuation study to provide continuing treatment to subjects with System Lupus Erythematosus (SLE).
Eligibility Criteria
Inclusion
- Have completed the HGS 1006-C1056 or HGS 1006-C1057 protocol through the Week 72 or Week 48 visits, respectively.
Exclusion
- Have developed any other medical disease or condition that has made the patient unsuitable for this study in the opinion of their physician.
Key Trial Info
Start Date :
May 30 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 9 2016
Estimated Enrollment :
738 Patients enrolled
Trial Details
Trial ID
NCT00712933
Start Date
May 30 2008
End Date
December 9 2016
Last Update
December 5 2019
Active Locations (110)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, 1015
2
GSK Investigational Site
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, C1419AHN
3
GSK Investigational Site
La Plata, Buenos Aires, Argentina, B1904CFH,
4
GSK Investigational Site
Rosario, Santa Fe Province, Argentina, 2000